netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 5: Infections - Full Chapter
Chapter Links...
 Details...
05.01.07  Expand sub section  Some other antibacterials
Pristinamycin 500mg Tablet
View adult BNF View SPC online View childrens BNF
Unlicensed Drug Unlicensed
Red

For staphylococcal infection or multi resistant organisms.

APCO November 2006.

 
   
05.01.07  Expand sub section  Chloramphenicol
Chloramphenicol
(Injection)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2010.

 
   
05.01.07  Expand sub section  Fosfomycin
Fosfomycin 3g sachets
View adult BNF View SPC online View childrens BNF
Third Choice
Green

Oral fosfomycin is the third or forth line option for patients with an acute, uncomplicated urinary tract infection, In line with SCAN guidelines.

APCO July 2018.

 

 
Link  NICE Evidence summary: Fosfomycin for resistant urinary tract infections
   
05.01.07  Expand sub section  Fusidic acid
Sodium Fusidate (Fucidin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2010.

 
Link  MHRA Safety Update: Systemic fusidic acid and interaction with statins
   
05.01.07  Expand sub section  Vancomycin and teicoplanin to top
Teicoplanin (Targocid®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO January 2005.

 
   
Vancomycin
(Oral)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Restricted for Clostridium difficile infection (CDI) or following Microbiology advice, in line with SCAN guidelines.

 
   
Vancomycin
(Infusion)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2010.

 
   
05.01.07  Expand sub section  Daptomycin
Daptomycin (Cubicin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For use at the NOC only on advice of ID or Microbiology Consultants in specific situations.

APCO January 2011.

 
   
05.01.07  Expand sub section  Linezolid
Linezolid
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2010.

 
   
05.01.07  Expand sub section  Quinupristin and dalfopristin
Quinupristin and dalfopristin (Synercid®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2010.

 
   
05.01.07  Expand sub section  Polymyxins
Colistimethate Sodium
View adult BNF View SPC online View childrens BNF
Formulary

Amber Traffic Light  For the treatment of Pseudomonas aeruginosa (PsA) colonised non-cystic fibrosis bronchiectasis. Colomycin is the product of choice. See OUH patient leaflet here

Red Traffic Light  For pseudomonas lung infection in cystic fibrosis as per NICE TA276. Funded by specialised commissioning (APCO May 2013).

 
Link  NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Link  NICE Evidence Summary: Non-cystic fibrosis bronchiectasis - colistimethate sodium
Link  MHRA: Colobreathe: risk of capsule breakage—new instructions for use
Link  UKMI: Safety Assessment for Different Formulations
   
05.01.07  Expand sub section  Rifaximin to top
Rifaximin (Targaxan®)
(Encephalopathy)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For preventing episodes of overt hepatic encephalopathy as per NICE TA337.

APCO May 2015.

 
Link  NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
   
05.01.07  Expand sub section  Fidaxomicin
Fidaxomicin (Dificlir®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only for recurrent clostridium difficile infection.

See SCAN guidelines.

APCO March 2014.

 
   
 ....
 Non Formulary Items
Bezlotoxumab  (Zinplava®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for preventing recurrent Clostridium difficile infection (NICE TA601 - terminated appraisal).

APCO November 2019. 

 
Dalbavancin

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Oritavancin  (Orbactiv®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Rifaximin  (Xifaxanta®)
(C.Diff and SIBO)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE evidence summary: Rifaximin for pouchitis
 
Tedizolid  (Sivextro®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary